Broncus Holding Corporation (HKG:2216)

Market Cap	579.79M +51.0%
Revenue (ttm)	47.72M -30.3%
Net Income	-118.94M
EPS	-0.25
Shares Out	527.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,871,434
Average Volume	704,647
Open	1.000
Previous Close	1.010
Day's Range	1.000 - 1.100
52-Week Range	0.800 - 3.720
Beta	1.12
RSI	28.61
Earnings Date	Mar 31, 2026

About Broncus Holding

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); BroncAblate Radiofrequency Ablation System, a transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation (TLD) Radiofrequency Ablation System for the treatment of COPD; H-Marker, a pulmonary surgical marker can be used...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2012
• Employees: 171
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2216

Financial Performance

In 2024, Broncus Holding's revenue was $8.13 million, a decrease of -20.71% compared to the previous year's $10.26 million. Losses were -$15.30 million, -45.52% less than in 2023.

Financial numbers in USD